She said the society had observed innovation in the sector during the Covid-19 lockdown and wanted to encourage DHBs to continue finding new ways of working to improve patient outcomes.
"We've seen some patient services moving online that have saved travel and time. We are working with some DHBs on trials using Cancer Society facilities to support consultations for those not able to manage the technology.
"The $282.5m catch-up campaign for planned care and elective surgeries will be welcome news for cancer patients impacted by the Covid-19 lockdown."
The Cancer Society welcome the new funding announced for Pharmac but said it was unclear if it would have any impact on the availability of cancer medicines.
"The funding increase, with no change in operating rules for Pharmac, signal a business-as-usual approach to medicine funding decisions," Chris Jackson, medical director of Cancer Society of New Zealand, said.
"There are stubborn and persisting problems in transparency, accountability, engagement with specialists, and timely decision making that are yet to be addressed with Pharmac. We can't see these addressed here and they need to be," Jackson said.